EXPO Stock Analysis: Exponent | NASDAQ
Engineering & Construction | NASDAQ, USA | Market Cap: 3.318m USD | 12M Return: 9.2% | US30214U1025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.7M
EPS Trend: 78.8%
Qual. Beats: 1
Rev. Trend: 96.0%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Exponent, Inc. (NASDAQ: EXPO) is a science and engineering consulting firm headquartered in Menlo Park, California, founded in 1967 (originally as The Failure Group, rebranded in 1998). The company operates through two segments-Engineering and Other Scientific, and Environmental and Health-delivering technical expertise across disciplines such as biomechanics, biomedical engineering, civil and structural engineering, materials and corrosion engineering, electrical and computer science, human factors, and vehicle engineering, as well as ecological, environmental, and health sciences. Its client base spans a broad range of industries, including chemical, construction, consumer products, energy, food and beverage, government, life sciences, insurance, manufacturing, technology, and transportation. The firms business model centers on deploying highly credentialed scientists and engineers to provide proactive product safety consulting, regulatory support, and reactive litigation support services, often serving as expert witnesses in complex technical disputes. As a mid-cap member of the Industrials sector, Exponent generates revenue primarily through billable hours on consulting engagements rather than product sales, which makes utilization rates and the depth of its technical talent pool key drivers of performance.
- Engineering consulting demand rises on complex product liability litigation
- Environmental and health segment grows amid tightening EPA chemical regulations
- Expert testimony engagements expand as corporate legal spending accelerates
| Net Income: 111.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 0.71 > 1.0 |
| NWC/Revenue: 24.38% < 20% (prev 51.86%; Δ -27.48% < -1%) |
| CFO/TA 0.18 > 3% & CFO 118.1m > Net Income 111.8m |
| Net Debt (14.1m) to EBITDA (153.3m): 0.09 < 3 |
| Current Ratio: 1.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.0m) vs 12m ago -5.04% < -2% |
| Gross Margin: 24.60% > 18% (prev 56.74%; Δ -32.15% > 0.5%) |
| Asset Turnover: 89.57% > 50% (prev 73.81%; Δ 15.77% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.24 (Total Current Assets 312.0m - Total Current Liabilities 157.8m) / Total Assets 652.7m |
| B: 1.07 (Retained Earnings 696.4m / Total Assets 652.7m) |
| C: 0.20 (EBIT TTM 143.1m / Avg Total Assets 706.1m) |
| D: 0.79 (Book Value of Equity 288.6m / Total Liabilities 364.1m) |
| Altman-Z'' = 7.22 = AAA |
| DSRI: 1.13 (Receivables 218.5m/171.0m, Revenue 632.5m/560.5m) |
| GMI: 2.31 (GM 56.74% / 24.60%) |
| AQI: 1.23 (AQ_t 0.31 / AQ_t-1 0.25) |
| SGI: 1.13 (Revenue 632.5m / 560.5m) |
| TATA: -0.01 (NI 111.8m - CFO 118.1m) / TA 652.7m) |
| Beneish M = -1.50 (Cap -4..+1) = CCC |
As of October 13, 2026, the stock is trading at USD 70.67 with a total of 462,863 shares traded. Over the past week, the price has changed by +2.79%, over one month by +2.14%, over three months by +11.63% and over the past year by +9.24%.
Current recommended Stop Loss: 67.10 (which is 5.1% or 1.9 ATR below the current price).
Exponent has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy EXPO.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 84 | 18.9% |
P/E Trailing = 31.2915
P/E Forward = 31.5457
P/S = 5.8501
P/B = 10.7805
P/EG = 2.0325
Revenue TTM = 632.5m USD
EBIT TTM = 143.1m USD
EBITDA TTM = 153.3m USD
Long Term Debt = 74.0m USD (estimated: total debt 80.7m - short term 6.76m)
Short Term Debt = 6.76m USD (from shortTermDebt, last quarter)
Debt = 80.7m USD (from shortLongTermDebtTotal, last quarter) (leases 80.7m already included)
Net Debt = 14.1m USD (calculated: Debt 80.7m - CCE 66.6m)
Enterprise Value = 3.33b USD (3.32b + Debt 80.7m - CCE 66.6m)
Interest Coverage Ratio = unknown (Ebit TTM 143.1m / Interest Expense TTM 0.0)
EV/FCF = 30.69x (Enterprise Value 3.33b / FCF TTM 108.6m)
FCF Yield = 3.26% (FCF TTM 108.6m / Enterprise Value 3.33b)
FCF Margin = 17.16% (FCF TTM 108.6m / Revenue TTM 632.5m)
Net Margin = 17.67% (Net Income TTM 111.8m / Revenue TTM 632.5m)
Gross Margin = 24.60% ((Revenue TTM 632.5m - Cost of Revenue TTM 476.9m) / Revenue TTM)
Gross Margin QoQ = 20.64% (prev 28.61%)
Tobins Q-Ratio = 5.10 (Enterprise Value 3.33b / Total Assets 652.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 80.7m)
Taxrate = 28.27% (44.1m / 155.8m)
NOPAT = 102.6m (EBIT 143.1m * (1 - 28.27%))
Current Ratio = 1.98 (Total Current Assets 312.0m / Total Current Liabilities 157.8m)
Debt / Equity = 0.28 (Debt 80.7m / totalStockholderEquity, last quarter 288.6m)
Debt / EBITDA = 0.09 (Net Debt 14.1m / EBITDA 153.3m)
Debt / FCF = 0.13 (Net Debt 14.1m / FCF TTM 108.6m)
Total Stockholder Equity = 355.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.83% (Net Income 111.8m / Total Assets 652.7m)
RoE = 31.48% (Net Income TTM 111.8m / Total Stockholder Equity 355.0m)
RoCE = 33.35% (EBIT 143.1m / Capital Employed (Equity 355.0m + L.T.Debt 74.0m))
RoIC = 21.84% (NOPAT 102.6m / Invested Capital 470.0m)
WACC = 7.05% (E(3.32b)/V(3.40b) * Re(7.22%) + D(80.7m)/V(3.40b) * Rd(0.0%) * (1-Tc(0.28)))
Discount Rate = 7.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.91 | Cagr: -2.13%
[DCF] Terminal Value 73.92% ; FCFF base≈113.5m ; Y1≈104.2m ; Y5≈92.2m
[DCF] Fair Price = 30.48 (EV 1.46b - Net Debt 14.1m = Equity 1.45b / Shares 47.5m; r=8.35% [WACC [floored]]; 5y FCF grow -10.23% → 2.50% )
EPS Correlation: 78.82 | EPS CAGR: 3.41% | SUE: 2.55 | # QB: 1
Revenue Correlation: 96.02 | Revenue CAGR: 6.96% | SUE: 1.86 | # QB: 4
EPS current Quarter (2026-09-30): EPS=0.62 | Chg30d=-3.87% | Revisions=+17% | Analysts=4
EPS current Year (2026-12-31): EPS=2.41 | Chg30d=-4.08% | Revisions=+50% | GrowthEPS=+16.4% | GrowthRev=+14.0%
EPS next Year (2027-12-31): EPS=2.72 | Chg30d=-4.14% | Revisions=+50% | GrowthEPS=+12.9% | GrowthRev=+8.5%
[Analyst] Revisions Ratio: +58% (up=8, down=1)